Abstract
Cancer immunotherapy has been accompanied by promising results over the past few years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune responses and promoting self-tolerance through modulating the activity of T-cells, activating apoptosis of antigen-specific T cells and inhibiting apoptosis of regulatory T cells. Programmed Cell Death Ligand 1 (PD-L1) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response, it can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. Based on these perspectives, PD-1/PD-L1 axis is responsible for cancer immune escape and makes a huge effect on cancer therapy. This review is aimed to summarize the role of PD-1 and PD-L1 in cancer, looking forward to improve the therapy of cancer.
Keywords
Immune systemPD-L1ImmunotherapyApoptosisCancer cellCancer researchCancerProgrammed cell deathCancer immunotherapyCytokineAntigenImmunologyBiologyMedicineBiochemistryInternal medicine
Affiliated Institutions
Related Publications
Cancer immunotherapy using checkpoint blockade
The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...
The biologic importance of tumor‐infiltrating lymphocytes
Detailed pathologic analysis has delineated a close association between intratumoral CD 8 + cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the...
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...
Publication Info
- Year
- 2020
- Type
- article
- Volume
- 10
- Issue
- 3
- Pages
- 727-742
- Citations
- 1630
- Access
- Closed
External Links
Citation Metrics
1630
OpenAlex
Cite This
Yanyan Han,
Dandan Liu,
Lianhong Li
(2020).
PD-1/PD-L1 pathway: current researches in cancer..
PubMed
, 10
(3)
, 727-742.